within Pharmacolibrary.Drugs.N_NervousSystem.N02A_Opioids.N02AX02_Tramadol;

model Tramadol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.68,
    Cl = 6.883333333333334e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0027,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006500000000000001,
    Tlag = 19.8,
    Vdp = 0.0026,
    k12 = 2.819444444444444e-05,
    k21 = 2.819444444444444e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tramadol</td></tr><tr><td>ATC code:</td><td>N02AX02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.9</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tramadol is an opioid analgesic used for the management of moderate to moderately severe pain in adults. It is a centrally acting analgesic that binds to mu-opioid receptors and also inhibits the reuptake of norepinephrine and serotonin. Tramadol is widely approved and used today in clinical practice for pain management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose.</p><h4>References</h4><ol><li><p>Thigpen, JC, et al., &amp; Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. <i>European journal of drug metabolism and pharmacokinetics</i> 44(5) 591–609. DOI:<a href=\"https://doi.org/10.1007/s13318-019-00552-0\">10.1007/s13318-019-00552-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31006834/\">https://pubmed.ncbi.nlm.nih.gov/31006834</a></p></li><li><p>Al-Qurain, AA, et al., &amp; Wiese, MD (2022). Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients. <i>European journal of drug metabolism and pharmacokinetics</i> 47(3) 387–402. DOI:<a href=\"https://doi.org/10.1007/s13318-022-00756-x\">10.1007/s13318-022-00756-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35167052/\">https://pubmed.ncbi.nlm.nih.gov/35167052</a></p></li><li><p>Yoo, O, et al., &amp; Lim, LY (2022). A randomised controlled trial of a novel tramadol chewable tablet: pharmacokinetics and tolerability in children. <i>Anaesthesia</i> 77(4) 438–448. DOI:<a href=\"https://doi.org/10.1111/anae.15650\">10.1111/anae.15650</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35083739/\">https://pubmed.ncbi.nlm.nih.gov/35083739</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02AX02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tramadol;
